Pharmaceuticals

Cipla Bloomberg: CIPLA IN EQUITY Reuters: CIPL.BO

Inhaler launches, visibility on biosimilars maintain optimism

Revenue growth of 8% YoY (and QoQ) for the quarter; EBITDA at 24%: Operating income grew 8% YoY (and QoQ) below our expectation of 10% for the quarter. This is owing to lower domestic sales growth and lower R&D income for the quarter. EBITDA margin at 24% was slightly below our expectation of \sim 25%. Increase in employee costs, sales force ramp-up and lower R&D income led to lower EBITDA margin and net profit margins. Lower tax-rate of 18% v/s our expectation of 20% supported net profit margins.

We are revising our FY12 EPSe to Rs17.7 from Rs18.5 due to lower than expected growth for the quarter but remain positive on the Company's overall growth prospects. We maintain our **BUY** recommendation with a TP of Rs355, an upside of 17% from the current levels.

Outlook

- Inhalers business continues to be a strong growth driver: The Company has secured approval for Seroflo inhaler in South Africa and can be expected to generate Rs1bn in peak sales. Seroflo Multi-Haler[™] (a combination of Salmeterol and Fluticasone) is a leading product globally (mkt. size: US\$10bn) for treatment of asthma. This approval provides further confidence in Cipla's ability to develop and market technologically complex inhaler products. Salbutamol inhaler in Europe continues to do well and Cipla is on track to launch 8 inhaler products by end-FY13. We estimate an EPS of Re1.0 in FY12E from the EU inhaler business.
- Biosimilar launch program firming up: The Company has invested in two biotech companies last quarter for development and manufacture of biosimilars. The India launch for biosimilars is on track and we expect the first product launch in early FY12 adding to India business growth.
- Domestic business all set to deliver: Sales force ramp up (added 600 reps) and new product launches will likely contribute to domestic growth ahead. We expect overall domestic business growth at 12% CAGR to FY12.
- Low R&D (technical know how) income this quarter, expected to touch Rs1.7bn for the year: We expect R&D income to contribute ~Rs1.7bn annually due to a strong US/EU generic pipeline. The company has a strong generic development pipeline in the US with 41 ANDAs under filing and another 45 ANDAs awaiting filing.

Y/E March (Rsmn)	FY08	FY09	FY10	FY11E	FY12E
Income from operations	42,157	52,343	56,043	63,039	71,755
EBITDA	8,316	12,183	13,123	15,911	18,566
EBITDA Margins (%)	19.7	23.3	23.4	25.2	25.9
Adj PAT	7,010	7,723	10,029	12,222	14,217
EPS (Rs)	9.0	9.9	12.5	15.2	17.7
ROE (%)	18.7	17.8	17.0	17.7	17.7
ROCE (%)	19.0	16.1	20.7	21.8	21.6
PE (x)	33.7	30.6	24.3	20.0	17.2
Price/BV(x)	6.3	5.4	4.1	3.5	3.0

Source: Company, Ambit Capital research

August 17, 2010

No Change

Recommendation: BUY



RESULT UPDATE

Analyst contact

Anshuman Gupta

Tel: +91 22 3043 3286 anshumangupta@ambitcapital.com

Vijay Chugh

Tel: +91 22 3043 3054 vijaychugh@ambitcapital.com

Recommendation


CMP:	Rs304
Target Price :	Rs355
Previous TP:	Rs370
Upside (%):	17%
EPS (FY12E):	Rs17.7
Change from previous (%):	-4

Stock Information

Mkt cap:	Rs252,800mn/US\$5,404mn		
52-wk H/L:		Rs364/251	
3M Avg. daily	v vol. (mn):	2	
Beta (x):		0.6	
BSE Sensex:		18,167	
Nifty:		5,452	

Stock Performance (%)							
	1M	3M	12M	YTD			
Absolute	-6.2	0.1	10.2	-6.0			
Rel. to Sensex	-7.1	-4.9	-5.8	-9.7			

Performance (%)





Source: Bloomberg, Ambit Capital research

Ambit Capital and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, investors should be aware that Ambit Capital may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Exhibit 2: Quarterly snapshot

	Q110	Q410	Q111	QoQ	ΥοΥ
Total Operating Income	13,760	13,747	14,798	8%	8%
Domestic Sales	6,519	5,688	6,752	19%	4%
Export Sales	6,876	7,602	7,659	1%	11%
Less: Excise Duty	142	115	137	18%	-4%
Net Sales	13,253	13,175	14,274	8%	8%
Other operating Income	508	572	524	-8%	3%
Cost of Goods Sold	6,067	6,108	6,702	10%	10%
Gross Profit	7,694	7,639	8,096	6%	5%
Gross Margin %	58.1%	55.6% <mark></mark>	54.7%		
Salaries, wages, other payments	950	999	950	-5%	0%
Other expenses	3,329	4,060	3,750	-8%	13%
Total Expenses	10,345	11,167	11,292	1%	9 %
EBITDA	3,415	2,580	3,507	36%	3%
EBITDA Margin %	24.8%	18.8%	23.7%		
Other Income	120	451	168	-63%	40%
PBDIT	3,535	3,031	3,674	21%	4%
Depreciation	458	495	548	11%	20%
Interest	105	5	1		
PBT	2,972	2,532	3,125	23%	5%
Tax (including deferred tax)	555	567	550	-3%	-1%
Tax Rate	19%	22%	18%	-21%	-6%
ΡΑΤ	2,417	1,965	2,575	31%	7%
Net profit	2,417	2,756	2,575	-7%	7%

Source: Company, Ambit Capital research

Exhibit 3: Income statement

Y/E March (Rsmn)	FY08	FY09	FY10	FY11E	FY12E
Income from operations	42,157	52,343	56,043	63,039	71,755
Gross sales	41,010	50,216	54,103	60,882	69,346
Less: Excise	907	610	522	551	617
Net sales	40,103	49,606	53,581	60,331	68,729
Other operating income	2,054	2,737	2,462	2,708	3,026
Total operating expenses	(33,841)	(40,160)	(42,919)	(47,129)	(53,189)
EBITDA	8,316	12,183	13,123	15,911	18,566
Depreciation and amortisation	(1,163)	(1,518)	(1,671)	(1,999)	(2,318)
Interest	(113)	(329)	(221)	(6)	(10)
Other income	1,339	(1,367)	1,072	1,000	1,100
Profit before tax	8,380	8,968	12,304	14,905	17,338
Provision for tax	(1,369)	(1,245)	(2,275)	(2,683)	(3,121)
Adj PAT	7,010	7,723	10,029	12,222	14,217
Extraordinary items [expenses/(gain)]			(950)		
Reported PAT	7,010	7,723	10,979	12,222	14,217

Source: Company, Ambit Capital research



Cipla

Exhibit 4: Balance sheet

Y/E March (Rsmn)	FY08	FY09	FY10	FY11E	FY12E
Shareholders funds	37,552	43,478	59,106	68,987	80,395
Capital	1,555	1,555	1,606	1,606	1,606
Reserves & surplus	35,997	41,923	57,500	67,381	78,789
Borrowings	5,405	9,402	51	154	254
Secured loans	141	28	4	4	4
Unsecured loans	5,264	9,375	47	150	250
Deferred tax liability (net)	1,492	1,642	1,792	1,922	2,600
Sources of funds	44,448	54,522	60,945	71,548	83,764
Gross block	22,018	26,933	28,973	34,473	39,973
Depreciation	(5,404)	(7,008)	(8,861)	(10,860)	(13,179)
Net block	16,614	19,925	20,112	23,613	26,794
Capital work in progress	2,331	3,663	6,842	6,842	6,842
Investments	935	801	2,464	3,200	3,800
Inventories	11,205	13,983	15,123	17,066	19,540
Sundry debtors	14,065	18,529	15,666	20,698	22,611
Cash and bank balances	797	534	620	4,773	10,600
Loans and advances	11,037	10,901	11,682	10,294	10,294
Other current assets	345	235	578	235	235
Total current assets	37,449	44,181	43,670	53,064	63,279
Current liabilities	8,710	10,129	9,980	11,831	12,743
Provisions	4,168	3,917	2,164	3,341	3,809
Total current liabilities and provisions	12,878	14,046	12,144	15,172	16,552
Net current assets	24,571	30,136	31,527	37,893	46,727
Uses Of funds	44,448	54,522	60,945	71,548	83,764
Book value per share (INR)	48	56	74	86	100

Source: Company, Ambit Capital research

Exhibit 5: Cash flow statement

Y/E March (Rsmn)	FY08	FY09	FY10	FY11E	FY12E
Cash flow from operations	7,707	10,841	11,976	14,221	16,535
Increase in Cash for working capital	4,044	7,129	1,735	3,946	3,007
Net Operating Cash Flow	3,663	3,712	10,241	10,275	13,529
Net purchase of fixed assets	(5,628)	(6,998)	(5,255)	(5,500)	(5,500)
Net purchase of investments	(1,109)	1,221	(383)	(236)	50
Net cash flow from investing	(6,737)	(5,777)	(5,638)	(5,736)	(5,450)
Proceeds from equity capital	-	-	6,691	-	-
Proceeds from LTB/STB	4,367	3,616	(9,588)	97	90
Others	(1,819)	(1,819)	(1,819)	(1,873)	(2,341)
Net cash flow from financing	2,548	1,797	(4,716)	(1,776)	(2,251)
Change in Cash and equivalents	(525)	(268)	(113)	2,764	5,827
Cash flow from operations	7,707	10,841	11,976	14,221	16,535
Increase in Cash for working capital	4,044	7,129	1,735	3,946	3,007
Net Operating Cash Flow	3,663	3,712	10,241	10,275	13,529
Net purchase of fixed assets	(5,628)	(6,998)	(5,255)	(5,500)	(5,500)
Net purchase of investments	(1,109)	1,221	(383)	(236)	50
Net cash flow from investing	(6,737)	(5,777)	(5,638)	(5,736)	(5,450)

Source: Company, Ambit Capital research



Exhibit 6: Ratios

Y/E March	FY08	FY09	FY10	FY11E	FY12E
ROE (%)	18.7	17.8	17.0	17.7	17.7
ROCE (%)	19.0	16.1	20.7	21.8	21.6
Inventory days	91	88	95	93	93
Debtors days	105	114	111	105	110
Fixed assets T/o ratio	2.5	2.6	2.8	2.7	2.7
Debt/equity	0.14	0.22	0.00	0.00	0.00
Net Debt/Equity	0.12	0.20	(0.01)	(0.07)	(0.13)
Current Ratio	2.9	3.1	3.6	3.5	3.8

Source: Company, Ambit Capital research

Exhibit 7: Valuation parameter

Y/E March	FY08	FY09	FY10	FY11E	FY12E
EPS, post exceptional (INR.)	9.0	9.9	12.5	15.2	17.7
Reported EPS	9.0	9.9	13.7	15.2	17.7
PE (x)	33.7	30.6	24.3	20.0	17.2
Price/BV(x)	6.3	5.4	4.1	3.5	3.0
EV/Sales (x)	5.7	4.7	4.3	3.8	3.3
EV/EBITDA (x)	29.0	20.1	18.6	15.1	12.6

Source: Company, Ambit Capital research



Explanation of Investment Rating

Investment Rating	Expected return (over 12-month period from date of initial rating)
Виу	>15%
Hold	5% to 15%
Sell	<5%

Disclaimer

This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Ambit Capital. AMBIT Capital Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities is available on request.

DISCLAIMER

- 1. If you are dissatisfied with the contents of this complimentary Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using the Report and AMBIT Capital Private Limited ("AMBIT Capital") shall not be responsible and/ or liable in any manner.
- 2. This Report has been issued by AMBIT Capital for the information of its clients/potential clients only.
- 3. If this Report is received by any client of an affiliate of AMBIT Capital, in addition to the provisions setout in this Disclaimer, its provision to the recipient is subject to the terms of business in place between the AMBIT Capital and such affiliate.
- 4. AMBIT Capital is a Stock Broker registered with Securities and Exchange Board of India Limited (SEBI) and so it is regulated by SEBI.
- 5. This Report is not and should not be construed as an investment advice to any client to acquire, subscribe, purchase, sell, dispose of, retain any securities or an offer to sell or the solicitation of an offer to purchase or subscribe for any investment or as an official endorsement of any investment.
- 6. If 'Buy', 'Sell', or 'Hold' recommendation is made in this Report such recommendation or view or opinion expressed on investments in this Report is not intended to constitute investment advice and should not be intended or treated as a substitute for necessary review or validation or any professional advice. The views expressed in this Report are those of the analyst which are subject to change and do not represent to be an authority on the subject. AMBIT Capital may or may not subscribe to any and/ or all the views expressed herein.
- 7. AMBIT Capital makes best endeavour to ensure that the analyst(s) use current, reliable, comprehensive information and obtain such information from sources which the analyst(s) believes to be reliable. However, such information has not been independently verified by AMBIT Capital or the analyst(s).
- 8. The information, opinions and views contained within this Report are based upon publicly available information and rates of taxation at the time of publication which are subject to change from time to time without any prior notice. Reports may be updated anytime without any prior notice to any and/ or all client(s).
- AMBIT Capital makes no guarantee, representation or warranty, express or implied; and accepts no responsibility or liability as to the accuracy or completeness or currentness of the information in this Report.
- 10. Please note that past performance is not necessarily a guide to evaluate future performance.
- 11. AMBIT Capital and its affiliates and their respective officers directors and employees may hold positions in any securities mentioned in this Report (or in any related investment) and may from time to time add to or dispose of any such securities (or investment).
- 12. Affiliate(s) of AMBIT Capital may from time to time render advisory and other services to companies being referred to in this Report and receive compensation for the same.
- 13. AMBIT Capital may act as a market maker or risk arbitrator or liquidity provider or may have assumed an underwriting commitment in the securities of companies discussed in this Report (or in related investments) or may sell them or buy them from clients on a principal to principal basis or may be involved in proprietary trading and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented in the supervisory board or on any other committee of those companies.
- 14. AMBIT Capital may sell or buy any securities or make any investment which may be contrary to or inconsistent with this Report.
- 15. This Report should be read and relied upon at the sole discretion and risk of the client.
- 16. The value of any investment made at your discretion based on this Report or income therefrom may be affected by changes in economic, financial and/ or political factors and may go down as well as up and you may not get back the full or the expected amount invested. Some securities and/ or investments involve substantial risk and are not suitable for all investors.
- 17. This Report is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied in whole or I n part, for any purpose. Neither this Report nor any copy of it may be taken or transmitted or distributed, directly or indirectly within India or into any other country including United States (to US Persons), Canada or Japan or to any resident thereof. The distribution of this Report in other jurisdictions may be strictly restricted and/ or prohibited by law, and persons into whose possession this Report comes should inform themselves about such restriction and/ or prohibition.
- 18. Neither AMBIT Capital nor its affiliates or their directors, employees, agents or representatives, shall be responsible or liable in any manner, directly or indirectly, for views or opinions expressed in this Report or the contents or any errors or discrepancies herein or for any decisions or actions taken in reliance on the Report or inability to use or access our service or this Report or for any loss or damages whether direct or indirect, incidental, special or consequential including without limitation loss of revenue or profits or any loss or damage that may arise from or in connection with the use of or reliance on this Report or inability to use or access our service or this Report.

© Copyright 2006 AMBIT Capital Private Limited. All rights reserved.

Ambit Capital Pvt. Ltd. Ambit House, 3rd Floor 449, Senapati Bapat Marg, Lower Parel, Mumbai 400 013, India. Phone : +91-22-3043 3000 Fax : +91-22-3043 3100

